Adimmune Corporation

4142

TW0004142005

Pharmaceuticals

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
27.05 ^TWD	0.00%		-1.10%	-18.40%

Mar. 28	Adimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 05	An unknown buyer acquire 2.14% stake in Adimmune Corporation from BioEngine Technology Development Inc. for NTD300 million.	CI

Adimmune Corporation authorizes a Buyback Plan.

November 10, 2022

The Board of Directors of Adimmune Corporation has authorized a buyback plan on November 11, 2022.

Latest news about Adimmune Corporation

Adimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
An unknown buyer acquire 2.14% stake in Adimmune Corporation from BioEngine Technology Development Inc. for NTD300 million.	Feb. 04	CI
Adimmune Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Adimmune Corporation Announces Change in Representative of its Institutional Director	Nov. 01	CI
Adimmune Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Adimmune Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Adimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Clover Bio Signs Exclusive Deal to Distribute Influenza Vaccine in China; Shares Climb 3%	23-02-20	MT
Clover Biopharmaceuticals, Ltd. Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China	23-02-19	CI
Tranche Update on Adimmune Corporation's Equity Buyback Plan announced on November 11, 2022.	22-11-21	CI
Adimmune Corporation's Equity Buyback announced on November 11, 2022 has closed with the repurchase of 5,000,000 shares, representing 1.17% for TWD 182.07 million.	22-11-20	CI
Adimmune Turns Profitable in January-September	22-11-14	MT
Adimmune Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-13	CI
Adimmune Corporation announces an Equity Buyback for 5,000,000 shares.	22-11-10	CI
Adimmune Corporation authorizes a Buyback Plan.	22-11-10	CI
Adimmune Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Tranche Update on Adimmune Corporation's Equity Buyback Plan announced on June 9, 2022.	22-08-09	CI
Adimmune Corporation's Equity Buyback announced on June 9, 2022, has closed with 3,000,000 shares, representing 0.7% for TWD 110.56 million.	22-08-08	CI
Adimmune Upbeat on H2 Revenue	22-07-27	MT
Adimmune Corporation announces an Equity Buyback for 3,000,000 shares, representing 0.7% for TWD 1,528.09 million.	22-06-09	CI
Adimmune Corporation authorizes a Buyback Plan.	22-06-08	CI
Adimmune Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Adimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Adimmune's Revenue Soars 25-Fold in February Amid High Demand of COVID-19 Test Kits	22-03-08	MT
Adimmune Corporation Announces the Approval of the Company's Quadrivalent Influenza Vaccine from China's National Medical Products Administration	22-02-11	CI

ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ADIMMUNE CORPORATION	-18.40%	350M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals